Scilex Pharmaceuticals

Scilex Pharmaceuticals is owned by Sorrento Therapeutics.

Sorrento Therapeutics is a company listed under the stock ticker SRNE (US).

View the org chart displaying its 12 main executives

Most searched biographies at Scilex Pharmaceuticals

• Jaisim Shah, Chief Executive Officer and Director
• Jay Chun, Director
• Laura Hamill, Director

Popular executive movements at Scilex Pharmaceuticals

• Elizabeth Czerepak, Executive Vice President, Chief Financial Officer and Chief Business Officer, has left the company  (posted on September 25 2023).
• Stephen Ma, who was Chief Accounting Officer, is promoted to Chief Financial Officer  (posted on September 25 2023).
• Tien Lee, Director, has left the company  (posted on September 6 2023).

Create your alert
to follow the executive moves at Scilex Pharmaceuticals.

Sorrento Therapeutics has 1,863 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).
• Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Alice Schardt-Rossmann - Managing Director at Dirk Rossmann
• Thierry Abribat - Chief Executive Officer at Amolyt Pharma

Learn more about the Pharmaceuticals industry >

Press releases by Scilex Pharmaceuticals

• News & Events – Scilex Holding
• News & Events - Scilex Holding
• News - Scilex Holding
• Scilex Announces Addition of ZTlido® to Express Scripts National Formularies - Scilex Holding
• Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives – SCILEX Pharmaceutical
• Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management – SCILEX Pharmaceutical
• Scilex Holding, A Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for Ztlido® Label Expansion – SCILEX Pharmaceutical
• Sorrento Therapeutics and Scilex Holding, a Majority Owned Subsidiary, Have Entered Into an Exclusive Licensing Term Sheet With Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndr
• Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020 – SCILEX Pharmaceutical
• Sorrento COVID-19 R&D October 13, 2020 Pipeline Call Details Released – SCILEX Pharmaceutical
• View more press releases Close

Social media about Scilex Pharmaceuticals

• Scilex Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Scilex Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Jaisim Shah

Call Scilex Pharmaceuticals at +1 610...

View the org chart

Register to receive your alert

Report an error